Latest News

Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress

View Press Release

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

View Press Release

Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023

View Press Release

Latest Presentation

Investor Presentation

Upcoming Event

Annual Meeting of Stockholders

Latest Financial Results

Q1 2023

Quarter Ended Mar 31, 2023

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

Company Overview

Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The company was founded in 2012, and since 2014 the company’s stock has been publicly traded on Nasdaq under the symbol ATRA.

Atara’s most advanced T-cell immunotherapy in development, tabelecleucel or tab-cel® (formerly known as ATA129), is being developed for the treatment of patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC).

Atara is also developing off-the-shelf, allogeneic ATA188 for the potential treatment of multiple sclerosis (MS).

Stock Snapshot

Investor & Media Contacts

Investor Relations

Eric Hyllengren
Chief Financial Officer
T: (805) 395-9669


Alex Chapman
Vice President, Corporate Communications & Public Affairs
T: (805) 456-4772

Transfer Agent

Computershare Trust Company, N.A.
P.O. Box 505000
Louisville, KY 40233
T: (781) 575-2879

Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.